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SYNTHESIS OF POLYMER COATED CERIA
NANOPARTICLES FOR BIOMEDICAL
APPLICATIONS

ing cerium oxide, some of which are associated with a polymer, including dextran. The colloidal compositions are useful
as imaging agents in technology requiring injectable chemicals for contrast agents. There is no mention of cerium oxide
coated with polymers having autocatalytic and antioxidant
properties.
U.S. Patent Publication 2006/0142749 to Robert Ivkov
discloses thermotherapeutic compositions for treating disease. The thermotherapeutic compositions include magnetic
nanoparticles that may be coated to enhance the heating properties of a bioprobe, particularly if the coating is a polymeric
material that can include dextran.
Thus, polymeric coatings including dextran have been
reported for use on magnetic nanoparticles and the results
seem promising in molecular imaging, monitoring and therapeutic treatment of disease.
It is desirable to find reliable solutions to use of nanoceria
particles with antioxidant properties in the treatment of many
human diseases that are due to the death of cells in specific
tissues or organs. The majority of those diseases are due to
accumulation of metabolic insults from reactive oxygen species originating within or outside of the cells. These diseases
include all forms of blindness whether hereditary, light-induced, or physical damage such as occurs in retinal detachment. In addition, damage due to ageing, stroke, cardiac
infarction, bums, etc, which proceed through reactive oxygen
species, can be addressed with the nanoceria particles synthesized according the present invention.

The present application claims the benefit of priority from
U.S. Provisional Patent Application Ser. No. 60/878,043 filed
on Dec. 29, 2006, which is incorporated herein by reference.
FIELD OF THE INVENTION
10

This invention relates to biological uses of nanoceria particles, and in particular to methods and compositions useful in
the synthesis of polymer coated ceria oxide nanoparticles for
biomedical applications.
15

BACKGROUND AND PRIOR ART
Cerium is a silvery metallic element, belonging to the
lanthanide group. Cerium oxide (Ce0 2 ) is used in precision
polishing and lapping applications. Ultra fine nano-size
cerium oxide, less than 10 nanometers, is more efficient for
coating purposes. Recently, it was reported by B. Rzigalinski
et al. that nanoparticles prolong the life of cortical neurons in
culture 4 fold over the cells without treatment, decrease the
intracellular Ca2+ concentration and prevent UV damage of
cortical neurons. See B. Rzigalinski et al., "Cerium Oxide
Nanoparticles Extend Cell Longevity and Act as Free Radical
Scavengers" at website www.med.miami.edu/nmbws/Rzigalinski 112. Based on its chemical characteristics, this effect is
partially due to a decrease of reactive oxygen species (ROS).
Various investigators have shown that nanoceria particles
possess antioxidant properties and have demonstrated survival of neuron cells in cultures against oxidative stress and
radiation. The greatest benefit of the nanoceria is its ability to
get inside the cells and provide protection from reactive oxygen species (ROS); other body systems and tissues can also be
protected from damage due to ROS.
However, the synthetic procedures for nanoceria reported
so far are not likely to be approved by the U.S. Food and Drug
Administration (FDA) because the synthesis procedures
involve the use of surfactants and other toxic materials.
In addition to the use of non-approved surfactants and toxic
materials, the published synthetic methods result in uncoated
nanoparticles which agglomerate in aqueous solution.
Further developments in biomedical research reveal the
efficacy of coated magnetic nanoscale particle compositions
for therapeutic uses. In Patent Publication W0/2003/005029
to Zhenghe Xu et al. iron and iron oxide particles are coated
with dextran for biological cell separation using magnetic
carrier technology. The dextran coating is used to prevent
mechanical instability of the particle in suspension.
U.S. Patent Publication 2003/0124,194 to Gaw et al. discloses amine functionalized superparamagnetic nanoparticles using a process that consists of coating magnetic nanoparticles with a carboxylated polymer then subsequently
reacting the carboxylated functionalized magnetic nanoparticles with carbodiimide and a large excess of diamine, after
which the amine-terminated nanoparticles are reacted with
bifunctional crosslinking agents and with various biomolecules.
U.S. Patent Publication 2005/0130167 to Gang Boa, et al.
provides multifunctional magnetic nanoparticle probe compositions for molecular imaging and monitoring wherein the
magnetic nanoparticle has a biocompatible coating, such as,
dextran, thereon.
U.S. Patent Publication 2006/0014938 to Groman et al.
describes stable aqueous colloidal lanthanide oxides, includ-
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SUMMARY OF THE INVENTION
A primary objective of the present invention is to provide a
facile, synthetic method for the formation of cerium oxide
(ceria) nanoparticles coated with a biodegradable polymer.
A secondary objective of the present invention is to provide
a synthetic method for the formation of cerium oxide (ceria)
nanoparticles coated with dextran, a biodegradable polymer
that can be scaled up for commercial production.
A third objective of the present invention is to provide
cerium oxide (ceria) nanoparticles coated with a biodegradable polymer that has physical properties that are substantially identical of the properties of uncoated nanoceria particles for therapeutic applications.
A fourth objective of the present invention is to provide
cerium oxide (ceria) nanoparticles coated with a biodegradable polymer with good solubility and stability in water and
phosphate buffer saline.
A fifth objective of the present invention is to provide a
facile, synthetic method for the formation of cerium oxide
(ceria) nanoparticles coated with dextran that is further
crosslinked with epichlorohydrin and ammonia, resulting in
an aminated dextran coated ceria nanoparticles to create a
targetable ceria nanoparticle.
A sixth objective of the present invention is to provide a
water stable, biodegradable polymer coated nanoceria preparation that is biologically active for administration to human
and other manimals.
A seventh objective of the present invention is to provide a
water stable, biodegradable polymer coated nanoceria preparation that has a long circulation time, such as, a plasma
half-life longer than one minute.
An eighth objective of the present invention is to provide a
facile, synthetic method for the formation of cerium oxide
(ceria) nanoparticles coated with polyacrylic or any other
polycarboxylic acid polymer that will result in a carboxyl
group functionalized nanoparticle. The ceria nanoparticles
coated with functionalized carboxy1groups are reacted with a

US 8,333,993 Bl
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diamine, such as ethylenediamine, to create an amine funcride such as, dextran, arabinogalactan and chitosan; the most
tionalized cerium oxide nanoparticle without the need for
preferred polysaccharide is dextran.
polymeric crosslinking.
The preferred composition has a plurality of dextrancoated cerium oxide nanoparticles with a UV profile exhibA preferred method for the synthesis of a plurality of
iting strong absorption below approximately 400 nm with
cerium oxide nanoparticles coated with a biodegradable polypeak absorption at approximately 300 nm and the physical
mer for antioxidant, free-radical scavenging and autocatalytic
properties of the dextran-coated cerium nanoparticles replibiomedical applications, includes preparing an aqueous
cate the physical properties of the uncoated nanoceria parcerium nitrate solution, mixing the aqueous cerium nitrate
ticles for therapeutic applications as antioxidants, free-radisolution with a biodegradable polymer to form a first mixture,
10 cal scavengers and autocatalytic agents.
adding the first mixture dropwise to an ammonium hydroxide
The more preferred composition has a plurality of dextransolution while continuously stirring to form a second mixture,
coated cerium oxide nanoparticles that form a colloidal suscentrifuging the second mixture containing ammonium
pension that is stable in water and also form a colloidal
hydroxide to settle any debris or large particles, purifying the
suspension that is stable in a phosphate buffer saline solution.
centrifuged mixture by ultrafiltration, and recovering a plu- 15
Further objects and advantages of the present invention
rality of non-agglomerated cerium oxide nanoparticles
will be apparent from the following detailed description of a
coated with the biodegradable polymer wherein the antioxipresently preferred embodiment which is illustrated schedant, free-radical scavenging and autocatalytic properties of
matically in the accompanying drawings.
the cerium oxide nanoparticles are unchanged from uncoated
cerium oxide nanoparticles.
20
BRIEF DESCRIPTION OF THE FIGURES
The preferred synthesis method has a biodegradable polymer that is at least one of a carbohydrate polymer, a synthetic
FIG. 1 shows the UV-visible absorption spectrum of the
polyol, a carboxylated polymer, and derivatives thereof, more
dextran coated nanoceria prepared in the present invention.
preferably, the carboxylated polymer is polyacrylic acid.
FIG. 2 is the fluorescence spectra of dextran coated cerium
It is also preferred that the carboxylated polymer is reacted 25 oxide nanoparticle O'-ex=283 nm) showing a characteristic
with a diamine selected from at least one of ethylene diamine,
fluorescence peak at approximately 410 nanometer (nm)
propylene diamine and hexane diamine, to provide an amiwavelength.
nated cerium oxide nanoparticle in a reaction that eliminates
FIG. 3 shows the measurement of zeta-potential in the
analysis of the stability of nanoparticle preparation against
the need for polymer crosslinking.
The preferred carbohydrate polymer for the synthesis 30 agglomeration within biological systems.
method of the present invention is a polysaccharide, such as
FIG. 4 shows the X-ray diffraction pattern ofnanocrystaldextran, arabinogalactan, chitosan and the like; most preferline cerium oxide coated with dextran in the present invention.
ably the polysaccharide is dextran.
FIG. 5 shows the X-ray photon spectroscopy spectrum of
In the preferred synthesis method the cerium nitrate solution contains approximately 2.0 to approximately 3.0 grams 35 the synthesized cerium oxide nanoparticles coated with dextran showing the presence of a mixed valence (Ce3+ and
of cerium nitrate to approximately 5 ml of water and the
plurality of dextran-coated cerium oxide nanoparticles has a
Ce4+) state.
FIG. 6A is a photographic image of a first solution of
UV profile exhibiting strong absorption below approximately
400 nm with peak absorption at approximately 300 nm.
dextran coated nanoceria after ultrafiltration with an Amicon
A preferred composition that is useful as a potent antioxi- 40 30 K filter.
dant in biomedical applications includes a plurality of nanoFIG. 6B is a photographic image of a second solution of
dextran coated nanoceria after the solution is concentrated
ceria particles coated with a biodegradable polymer selected
using a 30K Centricon concentrator.
from at least one of a carbohydrate polymer, a synthetic
polyol, a carboxylated polymer, and derivatives thereof. The
FIG. 7A is a transmission electron microscopy (TEM)
more preferred carboxylated polymer is polyacrylic acid. The 45 image of the dextran coated ceria nanoparticles showing the
preferred carbohydrate polymer is a polysaccharide, such as,
size and dispersity of the ceria crystals.
dextran, arabinogalactan and chitosan; most preferably, the
FIG. 7B is a high resolution transmission electron microspolysaccharide is dextran.
copy (HRTEM) image of the dextran coated ceria nanoparticles showing that the coating does not affect the crystallinIn the preferred composition, the plurality of dextrancoated cerium oxide nanoparticles has a UV profile exhibit- 50 ity.
ing strong absorption below approximately 400 nm with peak
FIG. 7C is a selected area electron diffraction (SAED)
image of a single ceria crystal showing that the dextran coated
absorption at approximately 300 nm and the physical properties of the dextran-coated cerium nanoparticles replicate the
ceria crystal is a face-centered cubic (FCC) phase crystal.
FIG. 8 is a graph showing the increase in particle size with
physical properties of the uncoated nanoceria particles for
therapeutic applications as antioxidants, free-radical scaven- 55 time on concanavalin addition.
gers and autocatalytic agents.
FIG. 9 is a graph showing reversible and successive shift in
In the preferred composition, the plurality of dextrantransmittance of dextran coated nanoceria particles after addcoated cerium oxide nanoparticles form a colloidal suspening hydrogen peroxide (Days 1-10).
FIG. lOA is a real-time image of dextran nanoceria solusion that is stable in water and form a colloidal suspension
60 tions without hydrogen peroxide on the left and with hydrothat is stable in a phosphate buffer saline solution.
A more preferred composition of matter that is useful as an
gen peroxide on the right at day one.
FIG. lOB is a real-time image of dextran nanoceria soluantioxidant, free-radical scavenger and autocatalyst in biomedical applications includes a plurality of nanoceria partions without hydrogen peroxide on the left and with hydroticles coated with a crosslinked-aminated biodegradable
gen peroxide on the right at day three.
FIG. lOC is a real-time image of dextran nanoceria solupolymer selected from at least one of a carbohydrate polymer, 65
a synthetic polyol, a carboxylated polymer, and derivatives
tions without hydrogen peroxide on the left and with hydrothereof. The preferred carbohydrate polymer is a polysacchagen peroxide on the right at day seven.
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FIG. lOD is a real-time image of dextran nanoceria soluThe first embodiment of the present invention provides a
tions without hydrogen peroxide on the left and with hydromethod and procedure for synthesizing a biodegradable polygen peroxide on the right at day ten.
mer coated ceria nanoparticle for antioxidant and autocataFIG. lOE is a real-time image of dextran nanoceria solulytic biomedical applications.
The second embodiment of the present invention provides
tions without hydrogen peroxide on the left and with hydroa method and procedure for synthesizing aminated crossgen peroxide on the right at day ten after adding fresh hydrolinked dextran coated ceria nanoparticles for antioxidant and
gen peroxide.
autocatalytic biomedical applications.
FIG. lOF is a real-time image of dextran nanoceria soluThe third embodiment of the present invention provides a
tions without hydrogen peroxide on the left and with hydro10 method and procedure for synthesizing non-crosslinked, cargen peroxide on the right at day twenty.
boxylated polymer coated ceria nanoparticles to provide an
FIG. llA is a graph showing the percent viability ofnormal
amine functionalized nanoparticle for antioxidant and autocardiomyocyte cell cultures untreated and treated with dextcatalytic biomedical applications.
ran coated nanoparticles, hydrogen peroxide and a combinaThe examples below provide further detail on the synthesis
tion of dextran coated nanoparticles and hydrogen peroxide.
15 and physical characterization of the biodegradable polymer
FIG. llB is a graph showing the percent viability ofnormal
coated ceria nanoparticles of the present invention.
dermal fibroblasts cell cultures untreated and treated with
dextran coated nanoparticles, hydrogen peroxide and a comExample 1
bination of dextran coated nanoparticles and hydrogenperoxide.
20
Synthesis ofDextran Coated Ceria Nanoparticles
FIG. 12 is an X-ray photon spectroscopy (XPS) spectra of
the aminated nanoceria showing the presence of a mixed
Under ambient conditions, a 1 M cerium nitrate solution
valence, ce+ 3 and ce+4 similar to the spectrum of dextran
(2.17 gin 5 ml of water) was mixed with a IM Dextran T-10
coated nanoceria that is not aminated.
(5 g in 10 ml of water) to form mixture (I). Under continuous
FIG. 13 is an X-ray photon spectroscopy (XPS) spectrum 25 stirring, the mixture (I) is then added dropwise to 30 ml of
of the polyacrylic acid coated nanoceria (PAA-nanoceria)
29% animonium hydroxide solution (Fischer, USA) forming
showing the presence of a mixed valence, ce+ 3 and ce+4
mixture (II). Mixture (II) is then stirred continuously for 24
similar to the spectrum of dextran coated nanoceria and amihours. After 24 hours of stirring, the solution turns from a
nated dextran coated nanoceria shown in FIG. 12.
light yellow to a deep brown color. The preparation is centri30 fuged at a rate of 4000 rpm for two 30-minute cycles to settle
DESCRIPTION OF THE PREFERRED
down any debris and large particles. The preparation is then
EMBODIMENTS
purified from free dextran by ultrafiltration using a 30 K
Amicon filter.
Before explaining the disclosed embodiments of the
present invention in detail it is to be understood that the 35
Example 2
invention is not limited in its application to the details of the
particular arrangements shown since the invention is capable
Crosslinking and Amination of Dextran Coated Ceria
with Epichlorohydrin
of other embodiments. Also, the terminology used herein is
for the purpose of description and not of limitation.
The term "nanoceria" is used interchangeably with 40
Dextran coated ceria nanoparticles are crosslinked with
"cerium oxide nanoparticles" and is used to refer to the
epichlorohydrin using following procedure under ambient
cerium oxide particles of multiple valences.
conditions:
The term "biodegradable polymer" is used herein to
To 3 ml (3 volume) of dextran coated nanoceria particle
describe a class of polymers that are non-toxic to mammals
preparation in Example 1, 5 mL (5 volumes) of5MNaOHare
and the environment and more specifically, include dextran, 45 added while stirring. Then, 2 mL (2 volumes) of epichloroderivatives of dextran such as reduced dextran, carboxyl
hydrin are added to the stirring solution. The ceria nanoparmethyl reduced dextran, a polyol polymer or carbohydtrate
ticle suspension is stirred vigorously for 8 hours at room
polymer, synthetic polyols, carboxylated polymers, such as
temperature. Then, 8.5 mL (8.5 volumes) of30% ammonia is
added and stirred overnight at room temperature. The next
polyacrylic acid, and other polysaccharides, such as, but not
limited to, arabinogalactan, and chitosan as disclosed in Gro- 50 day, the excess epichlorohydrin and ammonia are removed by
man et al. U.S. Patent Publication 2006/0014938 and Gaw et
ultrafiltration and the nanoparticle buffer is exchanged to
0.025 M Na-Citrate buffer pH 8. At this point, the aminated
al. U.S. Patent Publication 2003/0124,194.
dextran nanoceria preparation can be concentrated without
In the present invention, the cerium oxide nanoparticles or
precipitation of the nanoparticles.
nanoceria are polymer associated, or, in other words, coated
with a biodegradable polymer. The polymer confers stability 55
Epichlorohydrin is used as the crosslinking agent in
in water and can be functionalized with carboxylic or amino
Example 2, however, it is understood by those skilled in the
groups for conjugation with proteins, peptides, oligonucleart that other crosslinking agents may be used, such as glutaraldehyde, bromide derivatives of cyanogens and the like.
otides, small molecules, and the like.
It is a primary concern that the physical properties of the
In general, the polymer coated nanoceria particles of the
present invention each have a size between approximately 1 60 biodegradable polymer coated ceria nanoparticles remain
nanometer (nm) to approximately 500 nm in diameter, prefunaffected by the coating which improves handling and applierably between approximately 1 nm and approximately 10
cation for biomedical purposes.
nm.
In FIG. 1, the UV profile for the dextran coated nanoceria
Methods of preparing the biodegradable polymer coated
is shown. Dextran coated ceria particles show strong absorpcerium oxide compositions for use as an antioxidant and 65 ti on below 400 nm with peak absorption maximum at 300 nm.
The UV profile of the dextran coated nanoceria prepared in
protection from damaging ultra violet (UV) radiation are
provided in detail below.
the present invention is similar to that obtained in previous
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work showing that naked or uncoated ceria nanoparticles
have well defined peak absorption around 305 run. Thus, the
UV profile of the coated and uncoated nanoceria is substantially the same.
In FIG. 2 the fluorescence spectra of dextran coated nanoceria particles of the present invention has a characteristic
fluorescence peak around 410 run and is similar to the fluorescence spectra of the uncoated nanoceria particles reported
by S. Sathyamurthy et al. in "Reverse Micellar Synthesis of
Cerium Oxide Nanoparticles" Nanotechnology 16 (2005)
1960-1964.
To analyze the stability of nanoparticle preparation against
agglomeration within biological systems, zeta-potential measurement is performed. In pure water, the zeta-potential measurements of oxide dispersions cover a wide range from -25
to 55 mV. Due to the presence of dextran polymer on the
surface of the nanoparticle, its charge distribution would be
affected and the zeta potential would be shifted toward more
positive and less negative values. The dextran coated nanoceria preparation of the present invention has a zeta potential of
-5.7 mV as shown in FIG. 3.
The X-ray diffraction (XRD) pattern for the dextran coated
nanoceria is shown in FIG. 4. The diffraction peaks found in
the coated nanoceria are in a good agreement with those
found in bulk ceria and preparation of uncoated nanoceria, as
determined by the earlier investigator (W. Chengyun et al,
2002, S. Sathyamurthy et al, 2005). The broadening of the
peak suggests that the particles are of small dimension. The
particle size, which can be calculated using the Scherrer
equation, is around 3 run, which is in agreement with the data
obtained by TEM. Also XRD confirms that it has (111 ), (220),
(311) and (331) plane which was compared with the data
obtained the JCPDF file.
X-ray photon spectroscopy (XPS) data in FIG. 5 show the
presence of a mixed valence state, indicating that the dextran
coating on the nanoparticle does not affect this key physical
property of nanoceria. The data also show that the amount of
Ce+ 3 ion in the nanoparticle is more than the amount of Ce+4
ion, in agreement with the small particle size (of less than 5
run) as reported by D. Schubert et al., Biochemical and Biophysical Research Communications 2006, 342, 86.
FIG. 6A is a photographic image of a sample of dextran
nanoceria in aqueous solution wherein the vial on the left
corresponds to a solution of dextran nanoceria obtained following the procedure we are disclosing in this invention disclosure, after ultrafiltration with an Amicon 30 K filter as
described in Example 1. When a sample of this solution is
concentrated using a 30K Centricon concentrator, a more
concentrated dextran coated nanoceria is obtained, as shown
in FIG. 6B, the vial on the right, with a darker solution. No
precipitation of agglomeration is observed in any of the two
solutions, showing the great stability ofthis nanoceria preparation in aqueous solution.
Further characterization of the dextran coated nanoceria
preparation is provided in FIGS. 7A, 7B and 7C showing the
high crystallinity of the nanoceria particles of the present
invention. FIG. 7A is a transmission electron microscopy
(TEM) image of the dextran coated ceria nanoparticles showing the size and dispersity of the ceria crystals. FIG. 7B is a
high resolution transmission electron microscopy (TEM)
image of the dextran coated ceria nanoparticles, showing that
the coating does not affect the crystallinity. FIG. 7C is a
selected area electron diffraction (SAED) image of a single
ceria crystal showing that the dextran coated ceria crystal is a
FCC phase crystal.
Concanavalin studies were used to verify the dextran coating of the ceria nanoparticles of the present invention.

Concanavalin is a protein with four binding sites, known to
bind carbohydrates. This protein has been used to induce the
clustering of dextran-coated gold nanoparticles and most
recently it was used in clustering iron oxide nanoparticles. It
is used to study how the clustering phenomenon changes the
optical (gold nanoparticles ), or magnetic (iron oxide) properties of the nanoparticles. It is used to verify whether the
dextran is associated to (coating) the nanoparticle. In these
studies, dextran coated nanoceria is incubated with concanavalin and an increase in the particle size is observed as
measured by dynamic light scattering (DLS). This increase in
"size" by light scattering is not due to an increase in the size
of the nanoparticles, but rather is due to the clustering of the
nanoparticles in solution. FIG. 8 shows that after 90 minutes
incubation with concanavalin, nanoparticle clusters of 650
run in size are observed thus, showing the increase in particle
size with time on concanavalin addition.
Autocatalytic behavior of dextran-coated nanoceria was
studied with addition of hydrogen peroxide. One of the most
interesting properties ofnanoceria is its autocatalytic behavior. The ability of these nanoparticles to reversibly switch
from Ce+ 3 to Ce+4 , is a key factor for their biological applications as an antioxidant, among others. Therefore, it is determined whether the dextran coating on the nanoceria preparation compromised its autocatalytic behavior. In these
experiments, the nanoparticles are oxidized using hydrogen
peroxide. It is observed that after adding hydrogen peroxide
to the nanoceria there is a red shift and also color changes to
dark brown (Ce+4 ). As the hydrogen peroxide decomposes
from the nanoparticle suspension, the observed brown color
starts to disappear and the solution color returns to yellow
(Ce+ 3 ) within ten days as shown in FIG. 9. In FIG. 9, note the
reversible and successive shift in transmittance of dextran
coated nanoceria particles after adding hydrogen peroxide on
day one a, % transmittance plotted against the wavelength, is
between approximately 475 run to approximately 700 run, at
day 2 b, % transmittance is between approximately 410 run to
approximately 600 run, day 3 c, % transmittance is between
400 run and approximately 550 run; days 4-10 d-j, after the
addition of hydrogen peroxide and the decomposition of
hydrogen peroxide nears completion, the plot of the % transmittance against wave length is within a narrower range
between approximately 400 run and approximately 450 run
wavelength, confirming the disappearance of the brown color.
Autocatalytic activity is represented Equation (1) below:
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FIGS. lOA-lOF are real-time images of dextran coated
nanoceria solutions with and without hydrogen peroxide.
FIG. lOA shows a dextran-coated nanoceria solution without
hydrogen peroxide on the left 5 and with hydrogen peroxide
on the right 10 at day one. FIG. lOB shows a dextran-coated
nanoceria solution without hydrogen peroxide on the left 15
and with hydrogen peroxide on the right 20 at day three. FIG.
lOC shows dextran nanoceria solutions without hydrogen
peroxide on the left 25 and with hydrogen peroxide on the
right 30 at day seven. FIG. lOD shows dextran nanoceria
solutions without hydrogen peroxide on the left 35 and with
hydrogen peroxide on the right 40 at day ten. FIG. lOE shows
dextran nanoceria solutions without hydrogen peroxide on
the left 45 and with hydrogen peroxide on the right 50 at day
ten after adding fresh hydrogen peroxide on the tenth day.
FIG. lOF shows dextran nanoceria solutions without hydrogen peroxide on the left 55 and with hydrogen peroxide on the
right 60 at day twenty. The real-time images confirm the
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autocatalytic activity shown in FIG. 9; there are color changes
as the hydrogen peroxide decomposes from contact with the
nanoparticle suspension.
With regard to biological activity, preliminary biological
data shows that, as expected, the dextran-coated nanoceria
preparation act as potent antioxidant agents. In these experiments, normal human cell cultures are exposed to hydrogen
peroxide. This treatment causes a high level of cellular stress,
similar to that experienced by cells under oxidative damage.
The data show that in the absence of dextran nanoceria
(DNC), from approximately 50% to approximately 95% of
the cells died upon addition of hydrogen peroxide, whereas
most of them survive this harsh treatment when in the presence of dextran coated nanoceria (DNC).
FIGS. llA and llB are graphs of percent viability of
normal cell cultures, cardiomyocytes and dermal fibroblast,
respectively. In FIGS. llA and llB, the control is untreated
and thus 100% viable; the cells treated with dextran coated
nanoceria (DNC) are 100% viable and the cells treated with a
combination of dextran coated nanoparticles (DNC) and
hydrogen peroxide are 100% viable. However, FIG. llA
shows that normal cell cultures of cardiomyocytes are
approximately 5% viable when treated with or exposed to
only hydrogen peroxide and FIG. llB shows that normal cell
cultures of dermal fibroblasts are approximately 50% viable
when treated with hydrogen peroxide without dextran coated
ceria nanoparticles (DNC). Thus, FIGS. llA and llB are
graphical illustrations of the effectiveness of dextran coated
ceria nanoparticles as potent antioxidant agents that promote
100% cell viability in the presence of deadly oxidizing
agents.
The crosslinking and amination of dextran coated ceria
with epichlorohydrin as discussed in Example 2 above, was
studied to determine whether the anti-oxidant properties of
the nanoceria particles could be extended to injectable or
targetable biomedical applications.
The dextran coated nanoceria prepared according to
Example 1 shows great stability in water and various aqueous
buffers, such as 0.1 M phosphate buffer, pH 7.4, without
compromising its autocatalytic and antioxidant properties.
However, the surface of this nanoparticle cannot be easily
modified with targeting ligands such as peptides, oligonucleotides and proteins. To advance these studies, the polymeric
dextran coating has been crosslinked on the surface of the
ceria nanoparticle using epichlorohydrin and further derivatized its surface with annnonia to yield an aminated dextran
coated nanoceria. As discussed earlier, it is known in the art to
use other crosslinking agents and the present invention incorporates by reference, other known crosslinking agents, such
as, but not limited to, glutaraldehyde, bromide derivatives of
cyanogens, and the like.
Preliminary characterization of this preparation shows that
indeed the dextran surface contains reactive amino groups
that can be used to conjugate targeting ligands and various
dyes, including near infrared dyes that would allow in vivo
optical tracking of the nanoparticle. Furthermore, this amine
group, which has a positive charge at physiological pH, can be
reacted with a succinic anhydrate, resulting in a carboxylated
or negatively charged nanoceria preparation, greatly expanding the conjugation capabilities of the aminated preparation.
FIG. 12 is an X-ray photon spectroscopy (XPS) spectrum
of the aminated crosslinked nanoceria showing the presence
of a mixed valence, Ce+ 3 and Ce+4 similar to the spectrum of
dextran coated nanoceria that is not aminated.
Physical properties of the aminated dextran coated nanoceria were analyzed by X-ray photon spectroscopy to determine whether the crosslinking procedure would affect the

presence of both Ce+3 and Ce+4 and therefore its biological
and autocatalytic activity. As shown in FIG. 12, the presence
ofboth Ce+ 3 and Ce+4 species in the aminated dextran coated
nanoceria are similar to those obtained with non-crosslinked
nanoceria. This indicates that crosslinking of the dextran does
not affect the dual valency (Ce+ 3 /Ce+4 ) in the nanoceria
preparation of the present invention and most likely will not
affect its autocatalytic/antioxidant properties. Biological uses
of the crosslinked, biodegradable polymer-coated nanoceria
include administration to human and other mannnals needing
antioxidant treatments to prolong cell life.
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Carboxylated Polymer Coating ofNanoceria
Particles
In another embodiment, following the procedure outlined
in Example 1, wherein under ambient conditions, a 1 molar
solution of a polyacrylic acid is used in place of the 1 molar
solution of dextran, nanoceria particles are coated with a
biodegradable polymer containing a plurality of carboxylic
groups (carboxylated polymer), wherein a portion of the carboxyl groups are associated with the cerium oxide surface and
a portion of carboxyl groups are exposed on the nanoparticle
surface and available for conjugation. The carboxylated
nanoparticle can be reacted with a diamine, such as ethylene
diamine, and correspondingly converted to an amine functionalized nanoparticle.
Synthesis Method.
The preparation of polyacrylic acid coated nanoceria
(PAA-nanoceria) involves the use of cerium (III) nitrate and
polyacrylic acid (PAA). 1 M cerium (III) nitrate (Aldrich,
99%) solution(2.17 grams in 5.0milliliters (ml) ofwater)was
mixed with 0.5 mM solution of PAA (Sigma) to form mixture
(I). With continuous stirring, the cerium nitrate and PAA
mixture (I), is added drop wise to 30.0 ml of29% annnonium
hydroxide (Sigma Aldrich, 30%) solution to form mixture II.
Subsequently, mixture (II) is stirred continuously for 24
hours; at this point, the solution has changed from a light
yellow to a deep brown color. Next, the stirred mixture (II) is
centrifuged at 4000 rpm for two 30 minute cycles to settle
down any debris and large particles. The centrifuged solution
is then purified from free PAA by ultrafiltration using 30K
molecular weight cut-off Amicon filter (Millipore, Inc.) The
resulting negative charge on the PAA-nanoceria is assessed
by zeta potential analysis.
Below is a schematic diagram (2) of the synthesis ofpolyacrylic acid coated nanoceria (PAA-nanoceria).
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Note that the nanoparticles are functionalized with carboxylic groups on the surface, which allows conjugation of
peptides, DNA oligonucleotides, proteins, antibodies and
small molecules for targeting applications, without the need
for cross-linking the polymer.
Furthermore, the carboxylic groups on the polyacrylic acid
nanoceria can be converted to reactive amine groups by the
reaction with a water soluble diamine, such as ethylene
diamine, in the presence of a water soluble carbodiimide as
disclosed in Gaw et al., U.S. Patent Publication 2002/
0124194 for coating of iron oxide nanoparticles as MRI contrast agents.
PAA-nanoceria possess similar autocatalytic activity as
regular, non-coated nanoceria, dextran coated nanoceria, and
aminated dextran coated nanoceria. In addition, PAA-nanoceria contains both Ce4 + and Ce3 + (mixed valance) on the
nanoparticle which is important for its autocatalytic and antioxidant activity as shown in FIG.13. The X-ray photon spectroscopy (XPS) image of polyacrylic acid coated nanoceria
(PAA-nanoceria) in FIG. 13 is substantially similar to the
X-ray photon spectroscopy (XPS) image of dextran coated
nanoceria and aminated dextran coated nanoceria shown in
FIG. 12. This indicates that the PAA-nanoceria will behave
like the other polymer coated nanoceria preparations disclosed herein.
Prior to the present invention, a facile, cost effective, nontoxic synthesis of biodegradable polymer coated nanoceria
particles was not available. The synthesis does not require
surfactants or vigorous experimental conditions and the endproduct is suitable for unlimited biomedical applications.
Prior to the present invention, it was not known that a
biodegradable polymeric coating of ceria nanoparticles
would not affect the autocatalytic and antioxidant properties
of the ceria nanoparticles.
A biodegradable polymer coated nanoceria exhibits good
solubility and stability in water and phosphate buffer saline.
The preparation has good stability over many days in the
buffer solutions which is advantageous over the preparations
which aggregate when redispersed in aqueous media. This
characteristic makes them suitable for biomedical applications and clinical use. Further, there is no problem with
agglomeration in aqueous solution over a long period of time,
as with preparations using a sol-gel technique as reported by
H. S. Potdar et al. in Materials Chemistry and Physics, 2002
74, 306.
Further advantages of the biodegradable polymer coated
cerium oxide nanoparticle include a suspension that can be
concentrated using ultrafiltration devices without agglomeration of the nanoparticles.
With regard to the second embodiment, the dextran coating
on the nanoparticle can be crosslinked with epichlorohydin
and ammonia, resulting in an aminated dextran coated ceria
nanoparticles. The major benefit of the crosslinked dextran
coating is the ability to form conjugates to various ligands,
such as peptides, antibodies, DNA-oligonucleotides, proteins
and small molecules, to create a targetable ceria nanoparticle.
This would allow targeting or "homing" of the nanoparticle to
the corresponding site of inflammation or disease.
All embodiments of the present invention are useful in
forming colloidal compositions which include nanoparticle
suspensions of cerium oxide coated with a biodegradable
polymer. The resulting colloidal composition is highly stable
in water and water-based buffers, such as phosphate saline
buffer and the like. The colloidal compositions are also suitable for concentration and sterilization by filtration.
Similar procedures have been used in the preparation of
carboxylated coated iron oxide nanoparticles, allowing for

the creation of targeted molecular imaging agent for MRI as
reported in Gaw et al. U.S. Patent Publication 2003/0124, 194;
the teaching with regard to use of carboxylated polymers is
incorporated herein by reference.
Some dextran coated iron oxide nanoparticles have been
approved by the FDA for various applications including MRI
imaging oflymphnodes as reported by M. G. Harisinghani, et
al. in New England Jl. ofMedicine 2003, 348, 2491.
The newly developed synthesis of biodegradable polymer
coated ceria nanoparticles presented herein would be ideal for
clinical applications and a candidate for FDA approval. It was
an unexpected finding that the physical properties of the
biodegradable polymer coated ceria nanoparticles remain
unaffected by the polymeric coating which substantially
improves handling and application for antioxidant and autocatalytic biomedical applications.
While the invention has been described, disclosed, illustrated and shown in various terms of certain embodiments or
modifications which it has presumed in practice, the scope of
the invention is not intended to be, nor should it be deemed to
be, limited thereby and such other modifications or embodiments as may be suggested by the teachings herein are particularly reserved especially as they fall within the breadth
and scope of the claims here appended.
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We claim:
1. A method for the synthesis of a plurality of polymercoated cerium oxide nanoparticles coated with a biodegradable polymer for antioxidant, free-radical scavenger and
autocatalytic biomedical applications, comprising the steps
of:
a) preparing an aqueous cerium nitrate solution containing
approximately 2.0 to approximately 3 .0 grams of cerium
nitrate to approximately 5 ml of water;
b) mixing the aqueous cerium nitrate solution with a biodegradable polymer to form mixture (I);
c) adding mixture (I) dropwise to an armnonium hydroxide
solution while continuously stirring to form mixture (II);
d) centrifuging the mixture (II) containing armnonium
hydroxide to settle any debris or large particles;
e) purifying the centrifuged mixture of d) by ultrafiltration;
f) recovering a plurality of non-agglomerated, polymercoated cerium oxide nanoparticles coated with the biodegradable polymer wherein the plurality of polymercoated cerium oxide nanoparticles has a UV profile
exhibiting strong absorption below approximately 400
nm with peak absorption at approximately 300 nm; and
g) contacting isolated biological cells with the plurality of
polymer-coated cerium oxide nanoparticles wherein the
antioxidant, free-radical scavenging and autocatalytic
properties of the polymer-coated cerium oxide nanoparticles are unchanged from uncoated cerium oxide nanoparticles.
2. The method of claim 1, wherein the biodegradable polymer is selected from the group consisting of a carbohydrate
polymer, a synthetic polyol, a carboxylated polymer, and
derivatives thereof.
3. The method of claim 2, wherein the carboxylated polymer is polyacrylic acid.
4. The method of claim 2, wherein the carboxylated polymer is reacted with a diamine selected from at least one of
ethylene diamine, propylene diamine and hexane diamine, to
provide an aminated cerium oxide nanoparticle in a reaction
that eliminates the need for polymer crosslinking.
5. The method of claim 2, wherein the carbohydrate polymer is a polysaccharide.
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6. The method of claim 5, wherein the polysaccharide is

selected from the group consisting of dextran, arabinogalactan and chitosan.
7. The method of claim 6, wherein the polysaccharide is
dextran.
8. A composition of matter that is useful as a potent antioxidant in biomedical applications that comprises:
a plurality of polymer-coated nanoceria particles in contact
with isolated biological cells wherein the plurality of
polymer-coated nanoceria particles is coated with a biodegradable polymer selected from at least one of a carbohydrate polymer, a synthetic polyol, a carboxylated
polymer, and derivatives thereof wherein the plurality of
polymer-coated cerium oxide nanoparticles has a UV
profile exhibiting strong absorption below approximately 400 nm with peak absorption at approximately
300 nm and the antioxidant properties of the polymercoated cerium oxide nanoparticles are unchanged from
uncoated cerium oxide nanoparticles.
9. The composition of claim 8, wherein the carboxylated
polymer is polyacrylic acid and derivatives thereof.
10. The composition of claim 8, wherein the carbohydrate
polymer is a polysaccharide and derivatives thereof.
11. The composition of claim 10, wherein the polysaccharide is selected from the group consisting of dextran, arabinogalactan, chitosan and derivatives thereof.
12. The composition of claim 11, wherein the polysaccharide is dextran and derivatives thereof.
13. The composition of claim 12, wherein the plurality of
dextran-coated cerium oxide nanoparticles has a UV profile
exhibiting strong absorption below approximately 400 nm
with peak absorption at approximately 300 nm.
14. The composition of claim 12, wherein the physical
properties of the dextran-coated cerium nanoparticles replicate the physical properties of the uncoated nanoceria particles for therapeutic applications as an antioxidant, freeradical scavenger and autocatalytic agent.
15. The composition of claim 12, wherein the plurality of
dextran-coated cerium oxide nanoparticles form a colloidal
suspension that is stable in water.
16. The composition of claim 12, wherein the plurality of
dextran-coated cerium oxide nanoparticles form a colloidal
suspension that is stable in a phosphate buffer saline solution.
17. A composition of matter that is useful as an antioxidant,
free-radical scavenger and autocatalyst in biomedical applications that comprises:
a plurality of polymer-coated nanoceria particles in contact
with isolated biological cells wherein the plurality of
polymer-coated nanoceria particles is coated with a
crosslinked-aminated biodegradable polymer selected
from at least one of a carbohydrate polymer, a synthetic
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polyol, a carboxylated polymer, and derivatives thereof
wherein the plurality of crosslinked-animated polymercoated cerium oxide nanoparticles has a UV profile
exhibiting strong absorption below approximately 400
nm with peak absorption at approximately 300 nm and
the antioxidant, free-radical scavenging and autocatalytic properties of the polymer-coated cerium oxide
nanoparticles are unchanged from uncoated cerium
oxide nanoparticles.
18. The composition of claim 17, wherein the carbohydrate
polymer is a polysaccharide.
19. The composition of claim 18, wherein the polysaccharide is selected from the group consisting of dextran, arabinogalactan and chitosan.
20. The composition of claim 19, wherein the polysaccharide is dextran.
21. The composition of claim 20, wherein the plurality of
dextran-coated cerium oxide nanoparticles has a UV profile
exhibiting strong absorption below approximately 400 nm
with peak absorption at approximately 300 nm.
22. The composition of claim 20, wherein the physical
properties of the dextran-coated cerium nanoparticles replicate the physical properties of the uncoated nanoceria particles for therapeutic applications as an antioxidant, freeradical scavenger and autocatalytic agent.
23. The composition of claim 20, wherein the plurality of
dextran-coated cerium oxide nanoparticles form a colloidal
suspension that is stable in water.
24. The composition of claim 20, wherein the plurality of
dextran-coated cerium oxide nanoparticles form a colloidal
suspension that is stable in a phosphate buffer saline solution.
25. A composition of matter that is useful as an antioxidant,
free-radical scavenger and autocatalyst in biomedical applications that comprises:
a plurality of polymer-coated nanoceria particles in contact
with mammalian cells in need of antioxidant treatments
to prolong cell life wherein the plurality of polymercoated nanoceria particles is coated with a crosslinkedaminated biodegradable polymer selected from at least
one of a carbohydrate polymer, a synthetic polyol, a
carboxylated polymer, and derivatives thereof wherein
the plurality of crosslinked-animated polymer-coated
cerium oxide nanoparticles has a UV profile exhibiting
strong absorption below approximately 400 nm with
peak absorption at approximately 300 nm and the antioxidant, free-radical scavenging and autocatalytic properties of the polymer-coated cerium oxide nanoparticles
are unchanged from uncoated cerium oxide nanoparticles.
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